{"entity":{"id":"nct04268706","kind":"trial","name":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","aka":["CHARIOT"],"tldr":"A phase 2 trial of Fludarabine, Bendamustine in hodgkin lymphoma, run by Tessa Therapeutics, active and no longer recruiting.","summary":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) is a phase 2 interventional study registered as NCT04268706 by Tessa Therapeutics, with 97 participants planned, started 2021-02-01 and due to reach its primary completion in 2025-05. Interventions recorded: CD30.CAR-T, Fludarabine, Bendamustine. Conditions listed: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04268706","url":"https://clinicaltrials.gov/study/NCT04268706"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","relapsed-refractory-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine","bendamustine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04268706","phase":"2","setting":"A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","sponsor":"Tessa Therapeutics","participation":[{"nct":"NCT04268706","source":"https://clinicaltrials.gov/study/NCT04268706","fetchedAt":"2026-10-07T16:53:17.424Z","studySha256":"c2b74c7bfbe9ab891b4c2f2efa5d841cadc1cf69d16904a17fe0ba9c535d22cb","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2023-04-05","leadSponsor":"Tessa Therapeutics","collaboratorCount":0,"minimumAge":"12 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":97,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2021-02-01","startedType":"actual","enrolled":97,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04268706/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}